Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments

[at noodls] – Meaningful Improvement in Median Overall Survival in Patients With Second-Line NSCLC Supports Advancing Bavituximab Into Phase III Development; Contract Manufacturing Revenue Tops $17 Million for Nine … more

View todays social media effects on PPHM

View the latest stocks trending across Twitter. Click to view dashboard

See who Peregrine is hiring next, click here to view